Heart Transplant Program

Embark on a journey of innovation and discovery as we explore the latest advancements and emerging technologies in heart transplantation, offering new possibilities for personalized medicine, organ preservation, and immune tolerance induction to enhance transplant outcomes and improve patient care globally.

• Ex Vivo Organ Perfusion: Cardiac transplant researchers investigate ex vivo organ perfusion techniques to preserve donor hearts, optimize organ function, and extend the viability of donor organs, offering opportunities to expand the donor pool and reduce transplant wait times for patients in need of cardiac transplantation.
• Regenerative Therapies: Cardiovascular scientists explore regenerative medicine approaches to cardiac repair and myocardial regeneration, utilizing stem cells, tissue engineering, and gene therapy strategies to promote cardiac tissue healing, enhance myocardial recovery, and improve outcomes for patients with end-stage heart failure.
• Immune Tolerance Induction: Transplant immunologists and immune geneticists investigate immune tolerance induction strategies to minimize the need for long-term immunosuppression post-transplant, utilizing novel immunomodulatory agents, regulatory T cells, and donor-specific tolerance protocols to achieve transplant tolerance and improve graft acceptance rates while reducing medication-related complications for heart transplant recipients.
• Clinical Trials and Outcomes Research: Cardiac transplant investigators conduct clinical trials and outcomes research to evaluate novel treatment strategies, immunosuppressive protocols, and patient management strategies in heart transplantation, offering patients access to cutting-edge therapies, innovative devices, and promising therapeutic approaches beyond standard of care options, contributing to advancements in cardiac transplant research, treatment optimization, and quality improvement initiatives to transform the future of cardiovascular medicine and improve patient outcomes globally.